Kesimpta’s multiple sclerosis launch continues to take off

The four multiple sclerosis therapies that have launched since Roche's Ocrevus entered the market in 2017 have come nowhere near surpassing Ocrevus in sales, although Novartis' Kesimpta, the star of the group, is showing strong growth that hint it could be on a path to closing the gap.

For now, Kesimpta’s revenues remain less than 40% of Ocrevus’, but the dynamics of their sales suggest that fraction could grow...